AMPH - Amphastar Pharmaceuticals Inc


Strong Growth and ImprovingStock Price Attractive


based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 22.38%
Operating Income Growth is 519.51%
Net Income Growth is 442.6%
Earnings Per Share (EPS) Growth is 414.29%
Net Margin is 8.74%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.1
Debt Ratio is 0.34
Current Debt to Net Income Ratio is 0.08
Total Debt to Total Assets Ratio is 0.12
Cash Flow is STRONG
Cash from Operations Growth is 61.75%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Amphastar Pharmaceuticals Inc (AMPH) -
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Jack Zhang
Employees - 1,980

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.